IVERIC bio GATHER2 Trial of Zimura® for Geographic Atrophy
IVERIC Bio (ISEE) announced that it received written agreement from the U.S. FDA under a Special Protocol Assessment (SPA) for the overall design of GATHER2, the pivotal clinical trial of IVERIC product Zimura® (avacincaptad pegol) for the treatment of . . .
This content is for paid subscribers.
Today’s Highlights July 6, 2021